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Abstract (247 words) 
Background 
Sex steroids can positively affect the brain and from this it would follow that high levels of sex 
steroids could be associated with better cognitive function in older men and women.  
Methods 
This Healthy Ageing Study sample comprised of 521 older participants (51% women) without 
dementia at baseline, with an age range from 64 to 94 years. Testosterone and sex hormone 
binding globulin were measured using the automated Immulite 2000 and analyzed in association 
with baseline memory, global cognitive function and decline (assessed using the Mini-Mental 
Status Examination or MMSE) and controlling for potential confounds such as age, education, 
vascular disease, smoking, diabetes, thyroid function, and body mass index. 
Results 
In healthy older men and women, optimal levels of testosterone were associated with better 
MMSE scores at baseline. Follow-up analyses indicated that in men, low testosterone levels 
(OR=.94, 95% CI=.88 to 1.00) were a risk factor for a sharp cognitive decline after two years, 
perhaps indicative of dementia. Associations were independent of covariates and baseline 
MMSE. Conversely, women at risk for a sharp drop in cognitive function showed some 
evidence for higher calculated free testosterone levels at baseline.  
Conclusions 
Results replicate earlier cross sectional findings that high levels of sex steroids are not 
associated with better cognitive function in older people. In men, age accelerated 
endocrinological change could be associated with dementia pathology.  
General Significance 
These data do not support increasing testosterone levels to prevent cognitive decline in men and 
women over 65 years of age. 
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Introduction 
Sex steroids can act on many pathogenic mechanisms thought to be implicated in age-related 
cognitive decline and dementia and the biological plausibility for estrogens to protect the aging 
brain has been called ‘its strongest suit’ 1. This is probably the main reason why many 
researchers have continued to investigate sex steroids as a potential prophylactic treatment for 
dementia and age-related cognitive decline, despite negative publicity surrounding the use of 
estrogens in the last decade. Large well controlled studies found that estrogen treatment and 
high estrogen levels increased dementia risk in women over the age of 65 years 2-4. This may be 
because older neurons are more likely to undergo pathological change and in this state do not 
benefit from an estrogenic environment, but instead exhibit acceleration of neuronal 
degeneration 5.  
Animal and cell culture studies have shown that testosterone can also affect the brain, 
either indirectly though its conversion into estradiol (the most potent estrogen), but also by 
acting directly on the brain through androgen receptors (AR). Hippocampal neurons implicated 
in memory loss in aging and dementia express both estrogen receptors (ER) as well as AR, as 
do many other brain areas implicated in cognitive function, such as the frontal lobes. 
Testosterone’s potential protective actions are similar to those of estrogens, such as reduction of 
oxidative stress and prevention of self programmed cell death. In cell cultures and in vivo 
animal models testosterone also promoted dendritic sprouting and increased expression of nerve 
growth factor in the hippocampus, decreased susceptibility to excitotoxicity in hippocampal 
neurons, reduced amyloid β-induced neurotoxicity in cultured hippocampal neurons and 
prevented accumulation of β-amyloid, and hyperphosphorylation of tau 6-10, which are all factors 
considered to be important in the pathogenesis of accelerated pathological  age-related cognitive 
decline, such as Alzheimer’s disease (AD), the most common form of dementia. It is unclear 
whether high testosterone levels are associated with worse cognition in those over 65 years of 
age, as is thought to perhaps be the case for estrogens 11. 
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Studies investigating endogenous sex steroid levels in association with cognitive 
function in older women and men have found a wide variety in the direction of results, ranging 
from positive, negative or no associations 11-13. Several cross-sectional studies reported positive 
associations between free testosterone levels (FT, the bioactive fraction not bound to sex 
hormone binding globulin or SHBG) and cognitive (e.g. memory) functions in older men 14-16 
(but see 17 who reported non significance of log transformed testosterone in adjusted analyses). 
In contrast, others found that high FT was associated with lower cognitive function in men of a 
large age-range (35 to 80 years 18, 19), but also that optimal total testosterone (TT) levels 
(assessed by investigating the quadratic association) did seem to exist for optimal memory 
performance in older men 19, 20. Longitudinal data, however, did not always confirm significant 
associations between baseline FT levels with later cognitive decline in men 21-23, but these often 
only included one testosterone measurement at baseline. A longitudinal study which used 
within-individual average (mean) values over  repeated evaluations showed that averaged higher 
FT levels were associated with less visual memory decline in older men, which remained 
significant in adjusted analyses. While baseline FT also predicted better memory function, a 
change in TT or FT, however, did not predict cognitive change over time 24. Traditionally less 
attention has been given to the association between testosterone levels and cognitive function in 
women. Testosterone levels in older women are low when compared to those of men. However, 
because testosterone can be converted into estradiol, relatively small differences in testosterone 
levels (in nmol/L) could potentially result in large differences in endogenous estradiol levels (in 
pmol/L). Negative associations were found to exist between memory function and testosterone 
levels in women 12, 16 but also positive associations were reported in two small studies (<n=40 25, 
26). There are thus indications that high levels of testosterone, similar to those of estrogens, are 
not beneficial for maintenance of cognitive function for women over the age of 65 years, while 
for men perhaps optimal levels exist, which may be additionally age-dependent. We further 
investigated the associations between testosterone, SHBG, cognition and potential mediators. 
Unfortunately no funding was available at this stage to include estrogen levels. 
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Materials and Methods 
The current sample of the Healthy Ageing Study comprised a subset of respondents originally 
recruited for the Medical Research Council Cognitive Function and Ageing Study (MRC 
CFAS). The MRC CFAS is a longitudinal epidemiological study, which is being carried out in 
six centres in England and Wales (urban Liverpool, Newcastle, Nottingham and Oxford, 
Cambridgeshire and Gwynedd). Participants from five centre (not including Liverpool) were 
randomly sampled from the lists of general practitioners in the area and the samples were 
stratified by age, with equal numbers in the age group 65-74 and 75 and above. Informed 
consent was obtained by all participants before the onset of the study. Interviews were 
conducted in the participant’s place of residence by trained interviewers. Details of the sampling 
method and interviews can be found on the website http://www.cfas.ac.uk 27, 28. All respondents 
were pre-screened for severe cognitive impairment indicative of dementia using i) the Mini-
Mental State Examination (MMSE) score 29, including only those with a score of 18 or above, 
and ii) the ‘organicity’ items from the Automated Geriatric Examination and Computer Assisted 
Taxonomy (AGECAT) system using the cut-off of ‘ O3 and above’ as indicative of an organic 
(dementia) diagnosis 30. This algorithm using both the MMSE and AGECAT has shown good 
sensitivity for dementia and depression in older people 30. For physical frailty, the Townsend 
disability scale 31 was employed using a cut-off of 8, below which participants were not 
included. Participants also had to have good competence in English and not participate in other 
MRC CFAS studies.  
Participants in this Healthy Ageing Study sub sample comprised of respondents from 
urban Nottingham drawn from within the city boundaries.  The total number who participated in 
the Healthy Ageing Study (including those from rural Cambridgeshire) was 2041. Sufficient 
funding was available to obtain blood samples from half of all participants. Individuals willing 
to provide a blood sample were recruited until at least 500 had been collected in each centre. 
76% of those approached were willing to give a blood sample and were visited at home by a 
nurse or phlebotomist a median of 6.5 weeks after the Healthy Ageing Study interview. Those 
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who were selected and consented to give blood were not substantially different from those who 
did not in terms of demographics, health, mood and morbidity (see 32). At the time of 
venepuncture in 1992/1993, self report data on health status, medication use and body weight 
and height (to calculate body mass index or BMI) were recorded. After venepuncture, blood was 
separated within 4 hours and stored in aliquots at –70 degrees Celsius before samples were 
assayed for testosterone and SHBG at Loughborough University in 2007.  
Testosterone and sex hormone binding globulin (SHBG) were assessed in duplicate (R2 
=.97 for testosterone, R2 =..99 for SHBG) using the automated Immulite 2000, a solid-phase, 
two- site competitive chemiluminescent immunoassay. The quoted assay range for testosterone 
is 0.7 to 55 nmol/L, with 0.5 nmol/L being the limit of detection. For men over 50 years of age, 
the quoted reference range is 6.28 to 26.7 nmol/L, while for women of this age it is <0.5 to 2.57 
nmol/L. Total and between Coefficients of Variation (CV) for the TT assay were reported to be 
under 15.4% and were most typically between 4-6% . Using this assay gives a positive bias at 
concentrations over 2 nmol/L 33. For SHBG the between assay CVs were reported to be lower 
than 8% and the within assay CVs were lower than 5%, but results were found to be biased up 
to 29% depending on the SHBG concentration 34. Optimal levels were calculated using quartiles 
for men and women separately. 
The Mini-Mental Status Examination (MMSE) 29 was used as a primary indicator of 
global cognitive function. A drop of more than 4 points on the MMSE at follow-up (which was 
an average of 2 years from baseline) was used as an indication of clinically relevant cognitive 
change possible indicative of a dementia process. In a study of preclinical AD 3 years prior to 
diagnosis, those who would develop clinical AD had an annual decline of 1.81 points on the 
MMSE 35. This would translate to a drop of about 4 points after a 2 year follow-up. As 
secondary cognitive measures, immediate and delayed recall performance of a news story 
(Logical Memory, Wechsler Memory Scale-Revised version 36) were used as tests for episodic 
verbal memory, which had been assessed at baseline only. For both test aspects the maximum 
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score is 24. It should be noted that delayed recall was assessed between 5 and 10 minutes after 
immediate recall, which is shorter than the recommended interval of 30 min.  
Health related covariates, which were earlier hypothesized to mediate the association 
between sex steroid levels and cognitive function, were obtained during the interview and 
included self reported diagnosed vascular morbidity (risk) factors, such as high blood pressure 
(BP), coronary heart disease (‘heart attack’), stroke, diabetes mellitus, current smoking, body 
mass index (using weight and height data), and thyroid status using thyroid stimulating hormone 
(TSH) and free thyroxine (FT4) levels, which had both been assayed within weeks after the 
interview (see for more details 32). Thyroid disease was assessed by self report and by using 
blood values with standard laboratory cut-offs 32 
Statistical analyses Descriptive analyses included t-tests (for continuous) and Chi 
square tests (for categorical data) to describe differences between men and women, as all 
analyses were stratified for sex (see table 1). Correlations were calculated using Spearman’s 
rank correlations. For cross- sectional data, general linear model analyses were performed using 
total testosterone (TT, in quartiles calculated for men and women separately) and sex hormone 
binding globulin levels (SHBG, used in a continuous format, as this variable was normally 
distributed in men and women) as the main independent variables to assess their association 
with the following dependent variables:  i) global cognitive function, as measured with baseline 
MMSE performance; ii) verbal memory, as measured by the immediate and delayed news story 
recall at baseline. For longitudinal data, the delta (change score) of the MMSE (=baseline – 
follow-up score) was used to assess cognitive change over a 2 year period.  
A binary variable was computed to perform logistic regression analyses to identify 
cases with accelerated cognitive decline, who may have been at risk for dementia. For this, a 
cut-off based on a drop of at least 4 points or more on the MMSE over 2 years was employed. 
Age at first interview (in years), years of further education, thyroid hormones (both log TSH 
and FT4 levels, which was normally distributed), and body mass index (calculated using body 
weight in kg by the square of height in m) were entered as covariates. In a second set of 
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analyses, the same models were used, but now additionally included self reported diagnosed 
vascular and other morbidity (stroke, high BP, heart attack, diabetes) and smoking as covariates 
using a stepwise backward model for all variables (p<0.05 for removal). Analyses were run with 
and without those with thyroid disease and excluding those who had a baseline MMSE score 
less than 25. We also substituted the calculated free androgen index (FAI= TT/SHBG x100, 
which gives a good correlation with physical separation measures in women, but not men 37) in 
these analyses for TT and SHBG to investigate whether this gave similar results to using TT and 
SHBG separately. In longitudinal analyses, baseline MMSE scores were also entered. For all 
analyses SPSS 14.0 was used with a p-value of 0.05. 
 
Results  
Descriptive analyses of demographics, health and cognitive status 
Average age of participants was 74 years of age (SD=6, range 64-94) and 51% of the sample of 
521 participants were women. Participants had received an average of 9.6 (SD 1.7) years of 
further education. Reflecting Healthy Aging cohort exclusion criteria, only 4% self reported 
poor health. Table 1 and Figure 1 show descriptive analyses including self reported morbidity, 
which was overall low. Twice as many men as women reported having been diagnosed with a 
heart attack in the past (p=0.01), but there were no other gender differences in other morbidity 
(Figure 1) or in current self reported smoking (17% of men and women, p=0.80). Most had an 
MMSE over 25 (table 1) and only 16.3% of men and 20.6% of women (p=0.06) complained of 
memory problems at baseline. 
Most participants were in the normal expected range for both TT and SHBG levels. 
However, only 55% of men had TT levels over 12 nmol/L and could thus be classified as 
eugonadal according to some criteria1 38. Overt hypogonadism was detected in 15.6% of men 
who had TT levels lower than 8 nmol/L 38, with 6% having TT levels lower than the detection 
limit of 0.5 nmol/L.  
                                                     
1 Although criteria for hypogonadism may vary between TT < 6 and 10 nmol/L 
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More than half (52%) of women had missing TT data (which were below the .50 
detection limit), but 7% had data over the normal range, with some even reaching the higher end 
of the range for men (e.g. at 34 and 36 nmol/L, these two were also outside 5 SD from the 
mean). The assay was done in duplicate producing similar results, so these were not simple 
typographical errors. The women with these high values were typically quite old (>85 years) 
and some had thyroid disease, but this would probably not explain such extreme values. 
Alternatively, fluid contents may have decreased during storage at -70 degrees in a subset of 
samples due to crystallization and/or insufficient sealing in a minority of tubes, subsequently 
resulting in an artificial increase in hormone levels. Because we could not further investigate 
whether these levels were caused by such artefacts or were perhaps due to natural fluctuations 
with age in the older women, it was decided to calculate separate quartiles for men and women, 
which would solve the issues regarding the missing data and the data at the higher end of the 
spectrum for women.  
- insert table 1 about here please - 
 
Cross sectional analyses of hormone status and cognitive function at baseline  
Spearman’s rank correlations showed that in women, SHBG was not associated with TT 
(p=.56)2. High SHBG and low FAI (but not TT, p=.,20) levels both had significant association 
with having a lower BMI (r=-.39, p=0.001, r=.35, p<0.001 respectively). High SHBG levels 
were also seen in those who were older (r=.16, p<0.01).  Lower SHBG levels were seen in those 
diagnosed with diabetes (z=-3.16, p<0.0001). There was a trend association between higher TT 
levels and better MMSE scores (r=-.11, p=0.08), although the evidence was weak.  
In men, low TT was associated with low SHBG levels (r=.42, p<0.0001). High TT and 
SHBG3 levels were both associated with having a lower BMI (r=-19, p<0.002, respectively r=-
.24, p<0.001). Having low TT levels was associated with high TSH levels (r=-.17, p<0.0001). 
High FAI (but not SHBG or TT) levels had an inverse association with age (r=-15, p=0.02). FAI 
                                                     
2 In women FAI was inversely associated with SHBG, r=-.65 p<0.0001, and positively with TT levels, 
r=.75, p<0.0001 
3 but not FAI, which was associated with both SHBG r=-38 and TT r=.61, both p<0.0001 in men 
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levels were lower in those diagnosed with stroke (confirmed by M-W U-test: z=-2.79, p<0.005, 
with a similar effect seen for TT).  An older age was associated with lower MMSE and memory 
function in men (both r=-.21, p <0.001), and in women (both r=-.16, p<0.01).  
- insert fig 1 about here please – 
 
In women, using general linear models, a significant association between optimal TT  
levels (in quartiles) and MMSE scores at baseline was detected [F(1,228)=4.39, p=0.01], with 
those who had TT levels between 0.50 and 1.09 nmol/L having the highest MMSE scores (see 
Figure 2). This was after adjustment for age [F(1,228)=5.43, p=0.02], SHBG (p=.39), FT4 
(p=.33), log transformed TSH levels (p=.18), BMI (p=.33) and education (p=.24). When 
vascular (risk) factors were additionally controlled for in separate analyses (with some evidence 
of a negative association for smoking, p=0.06), results remained otherwise unchanged (for TT 
tertiles, F(3, 222)=3.10, p=0.05). Analyses (excluding those with thyroid disease, an MMSE 
score lower than 25 and controlling for age, education, BMI, SHBG and thyroid hormone (TSH 
and FT4) levels, vascular disease, smoking and diabetes) also showed a significant association 
for TT tertiles levels (p=0.02). However, there was no significant association between memory 
or an average drop in MMSE scores over two years with baseline TT, SHBG or FAI levels for 
women, in or excluding those with thyroid disease, with or without control for covariates. There 
was some evidence that TT tertiles (p=0.09 in adjusted analyses) were associated with better 
performance of the delayed recall. Women in the highest TT quartile recalled 10.46 (+/- .63) 
words after a delay, while women in the lowest quartiles recalled 9.2 words  (+/-.41).  
 
- insert fig 2 about here please –- 
 
In men, using general linear models, no significant associations were found between TT 
quartiles or SHBG levels and cognition, as measured by baseline memory or MMSE 
performance, or by using the average drop in MMSE scores over a 2 year follow-up. Only an 
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older age (F(1,245)=20.84, p<0.0001 resp. F(1,244)=15.92, p<0.0001) was associated with, 
respectively, a lower baseline MMSE and a lower immediate recall performance. There was 
some evidence of associations with high log transformed TSH levels (F(1,245)=2.68, p=0.10 
and p=0.074). For delayed recall only an older age (p<0.0001) predicted significantly lower 
scores. SHBG (p>.50) and TT (p>.50) levels did not have significant contributions in these 
analyses, which were further controlled for FT4 levels, BMI, and education.  
When those with thyroid disease and MMSE scores less than 25 were excluded and age, 
education, SHBG and thyroid hormone (TSH and FT4) levels, BMI, smoking and vascular and 
other disease (stroke, high BP, heart attack, diabetes) were controlled for in analyses of baseline 
MMSE, age (p=0.001), education (p=0.001) and some evidence for TT tertiles was seen (F(3, 
213)=2.17, p=0.09), but none of the other variables came into the equation. Post hoc pairwise 
comparisons (see Figure 3) revealed optimal TT levels for optimal MMSE performance in men, 
where those who had TT levels in the last quartile (>16.59 nmol/L) also had significantly lower 
MMSE performance than those of the second (p=0.02), with similar, trends for the third 
(p=0.06) and lowest quartiles (P=0.09). These results were not seen for memory or the 
calculated average drop in MMSE scores over time. We subsequently calculated a new binary 
variable for those who may have been at risk for dementia and had experienced a drop of 4 or 
more points on the MMSE within the two years of follow-up. 
insert fig 3 about here please 
 
Analyses of participants who experienced sharp cognitive decline over time versus controls 
 Sex stratified Chi-square analyses of those (30 men, 35 women, including those with thyroid 
disease) who would show a sharp drop in MMSE performance at follow-up, showed that these 
cases were at least twice more likely to already report memory problems at baseline (in men: 
30% versus 15% of controls, p=0.04, in women: 25% versus 9%, p=0.008). Male cases (but not 
female cases, p=.78) were 10 times more likely to have an MMSE score lower than 25 at 
baseline (16.7% versus 1.6% , p<0.001) indicating that the cognitive decline at follow-up was 
                                                     
4 This disappeared when those with thyroid disease were excluded 
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probably related to an ongoing dementia process, despite screening for this at baseline using the 
AGECAT algorithm. These analyses revealed no differences between cases and controls in self 
reported vascular morbidity, for the diagnoses of heart attack, stroke, high blood pressure, 
diabetes (p all > .25) or for current smoking at baseline. In female cases, the risk for thyroid 
disorders was slightly higher than that in controls (p=0.003) with 5.6% of women cases (versus 
0% of controls) having clinical hypothyroidism (either self reported or confirmed by TSH and 
FT4 levels) and 2.8% (versus 1%) of cases having clinical hyperthyroidism5.  
Analyses of 13% of men (n=26 versus n=172 controls) and 14% of women (n=29 
versus n=172 controls) without thyroid disease6 who would show a sharp drop in MMSE at 
follow-up showed that these already also had worse baseline memory (both immediate and 
delayed recall with an average of around 3.5 words less recalled on both test aspects in cases 
compared to controls). There were no significant baseline MMSE differences for this selected 
sample (both cases and controls scored around 27.84). However, at the 2 year follow-up, the 
average MMSE score was still 27.80 (SD=1.66) in controls, but was down to an average of 
21.48 (SD=2.25) in cases. There were only small differences in age (male controls were on 
average 1.66 years younger, and this was 2.53 years on average for female controls) and 
education (with a 0.70 year of further education more in control men and 0.04 year in women) 
and also no differences in BMI, diabetes, vascular disease (risk) factors (all p>.38, although 
there was some association for smoking, p=0.07) or either of the thyroid hormones (p>.50).  
However, FAI levels were significantly lower in male cases (average 22, SD=14) than 
those in controls (average 29, SD=14, p=0.04) at baseline. There were also weak evidence in the 
expected direction for TT (average 11 nmol/L SD=8 for cases versus 13 SD=6, p=0.09 for 
controls) and SHBG (average 54 nmol/L SD=24 for cases versus 47 SD=19, p=.09 for controls) 
                                                     
5 No distinction here was made for those who were treated or not as some were over or undertreated with thyroid 
hormones as laboratory values suggested by comparing these to self reported diagnosed thyroid morbidity 32.
 Hogervorst E, Huppert F, Matthews FE, Brayne C. Thyroid function and cognitive decline in the MRC 
Cognitive Function and Ageing Study. Psychoneuroendocrinology. 2008;33(7):1013-1022.. 
6 there were no significant differences in cases (n=30 men, n=35 women) and controls for TSH and FT4 levels, but as 
thyroid disease can affect both bioavailable sex steroid levels and cognition, these were excluded from these analyses 
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levels. In women this was not the case, instead there was some evidence for the reverse (FAI in 
controls on average was 3 (SD 7), for cases on average was 6 (SD=11, p=.067).  
 
Multivariable  analyses to establish risk factors for sharp cognitive decline 
Using multivariable logistic regression analyses showed that in men, a sharp drop in MMSE 
performance of at least 4 points over 2 years (which may have been indicative of dementia) was 
significantly associated with high SHBG levels (OR=1.02, 95% CI=1.00 to 1.05, p=0.02) and 
independently with low TT levels (OR=.93, 95% CI=.87 to .99, p=0.03) when controlled for 
age, BMI, education, FT4,  log TSH levels and baseline MMSE performance. Additional 
control for vascular (risk) factors in separate analyses had little effect on the estimates. In 
similar analyses, the FAI also gave a risk reduction for a sharp cognitive drop (OR=.95, 95% CI 
=.92 to .99, p=0.03), similar to the results of TT models. Entering TT quartiles using simple 
contrasts in these logistic regression analyses showed that only men who had TT levels in the 
upper quartile (more than 16.59 nmol/L) had significantly less risk for a sharp drop in MMSE 
performance (OR=.27, 95% CI=.08 to .93, p=0.04), when compared to men who had TT levels 
equal to or lower than 9.45 nmol/L (which was the reference value). There was no increase in 
risk for men who were in the ‘gray area’ between 12.65 and 9.45 nmol/L. Entering the 
curvilinear TT term did not give a better fit than the linear term in these analyses. In women, in 
similar analyses only trend effects remained for high log TSH (OR=2.21, p=0.06) to predict a 
sharp drop in cognitive function at follow-up.  
Analyses excluding participants with thyroid disease and those with an MMSE below 
25 at baseline did not substantially alter results for men with regards to TT (OR=91, 95% 
CI=.84 to .99), although now SHBG no longer had a significant association with a sharp drop in 
MMSE scores (OR=1.02 95% CI =1.00 to 1.04). There was some evidence (p=0.07) for high 
normal FT4 levels (similar to results of the larger cohort) to confer a 26% higher risk for a 
substantial drop in MMSE scores. These analyses were also controlled for age, log TSH and 
                                                     
7 because TT (average 3.5 nmol/L, SD=8 in cases, average 1.4 nmol/L, SD=4 in controls, p=.16) and SHBG (average 
64 nmol/L, SD=33 versus average 58 nmol/L, SD=28, p=0.30) levels were both non significantly higher in female 
cases 
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BMI, which were all non significant and also controlled for further years of education (OR=.61, 
95% CI=.38 to .99) and baseline MMSE (OR=1.63, 95% CI=1.07 to 2.48) which did contribute 
significantly to the equation. When in separate analyses vascular risk factors were additionally 
controlled for, TT (OR=.91, P=0.02) and SHBG (OR=1.03, p=0.02) still significantly 
contributed to risk of a sharp drop in cognitive function in men, as well as FT4 (OR=1.16, 
p=0.04), and smoking (OR=2.61, p=0.05). Excluding those with thyroid disease and MMSE 
scores less than 25 did not alter these analyses. When substituting FAI (OR=.95, 95% CI=.92 to 
.99, p=0.02) for TT and SHBG, results were not substantially different. With additional control 
for vascular factors, thyroid hormones (or thyroid disease) and the other covariates, for FAI 
results also remained unchanged (OR=.97, 95% CI=.94 to 1.00, p<0.05) which was the only 
variable left in the equation to significantly predict cognitive decline using the stepwise 
backward model. In analyses pertaining to women, only old age was entered as a non significant 
predictor for a sharp cognitive decline.  
 
Discussion 
This study showed sex differential associations of TT levels with cognition in older people 
similar to those reported in earlier studies. In older women and men, optimal TT levels were 
found at baseline to be associated with better global cognitive function, as measured with the 
MMSE, but not with memory function. Only in men, did high TT and FAI at baseline protect 
against a sharp drop in cognitive function after a 2 year follow-up. However, men with such 
high TT levels (>16.59) already had lower baseline MMSE scores and perhaps would thus show 
a more gradual slope of decline. On the other hand, these analyses were controlled for baseline 
MMSE scores. Thyroid results of this sample replicated the findings of the larger cohort which 
included rural Cambridgeshire 32. 
In MRC Challenge, in women of a similar age, high TT levels had a negative association 
with memory and speed of information processing 12. We could not replicate significant 
memory effects in the current Healthy Ageing sample, but differences in the sensitivity of the 
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memory test used (as discussed earlier in 32) may at least partly explain this. In addition, in 
MRC Challenge 12, estradiol was entered simultaneously in analyses, which was shown to affect 
the outcome (i.e. without estradiol, associations of verbal memory with TT were no longer 
significant), but this variable was unfortunately not available for the Healthy Ageing cohort. In 
MRC Challenge no significant associations of TT with the MMSE was found, but these were 
reported in larger another cohort of women of a similar age 39 and power issues may have 
accounted for finding a lack of significance of hormones on MMSE scores  in the MRC 
Challenge cohort.  
In contrast, in the present study, baseline FAI levels were slightly higher in women who 
were later shown to have a sharp drop in cognitive function over time. These results are 
reminiscent of those of the OPTIMA cohort, which showed that female AD cases had both 
higher estrogen and testosterone levels than controls in analyses controlled for a wide variety of 
potential confounding health-related variables 4, 11. As baseline TT optimal levels for women 
were within the normal range (between .90 and 1.09), treatment with testosterone, which may 
increase levels beyond this range, may thus not be advised to sustain cognitive function over 
time in older women. This would be in line with recent recommendations for estrogen 
treatment, but may also suggest that testosterone is not an appropriate alternative for estrogens 
in women over the age of 65 years to prevent cognitive decline 11. Small treatment trials 
focusing on cognitive improvement using testosterone were usually done in combination with 
estrogens in relatively recently menopausal women and were only short term 11. It is unclear 
whether long term exposure to higher testosterone levels might confer risk for dementia and 
accelerated cognitive decline in older women, as may be the case for estrogens. Meta-analyses 
showed that for both older women with dementia and middle-aged surgically menopausal 
and/or symptomatic women, positive effects of estrogen treatment did not exceed 4 months 40, 41 
and were actually reversed after 1 year of treatment in some studies 42. Some authors have 
suggested that high levels of gonadotropins are a more important target for research than sex 
steroids 43-46 and there is substantial evidence for this hypothesis. For instance, transgenic mice 
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which overexpress luteinizing hormone (LH), but which LH receptors are silenced do not 
exhibit the memory impairment similar transgenic animals with functional LH receptors show 
47. Data shown at the Alzheimer’s Association meeting in Madrid 2006 by Voyager 
pharmaceuticals indicated that leuprolide acetate (which lowers gonadotropin levels such as LH, 
but thus also (indirectly) estrogens and testosterone levels) improved cognitive function in AD 
cases. It could be proposed that the reduction of high levels of estrogens and perhaps also 
testosterone actually led to improvement in these cases rather than (or as well as) the reduction 
in neurotoxic high levels of LH (see article by Casadeus et al. in this issue).  
Significant positive associations between TT levels and MMSE performance at baseline 
were found in men of the Healthy Ageing sample, but only after control for diabetes, vascular 
and thyroid morbidity and after excluding participants with an MMSE score lower than 258. 
Earlier cross-sectional findings perhaps using fewer covariates (e.g. not excluding those with 
thyroid disease, not controlling for a wide range of vascular morbidity) in analyses also did not 
find significant associations between sex hormone levels and the MMSE performance in men, 
although significant associations were detected between testosterone levels and other cognitive 
measures  12, 24. In addition, in the BLSA, a greater increase in risk of Alzheimer’s disease with 
low FT was detected at follow-up 49. Similarly, in men of the Healthy Ageing sample, high TT 
and FAI were shown to protect against a sharp drop in cognitive decline, which was possibly 
indicative of dementia. This was independent of their baseline MMSE performance, SHBG 
levels, vascular and thyroid disease, smoking and BMI, as well as age and education. These 
results are also reminiscent of OPTIMA data and other cohorts, where men with Alzheimer’s 
disease had lower levels of TT and FAI than controls, when controlling for multiple 
confounding factors related to health and morbidity, such as medication use, BMI, alcohol 
abuse, smoking, and diabetes 50. On the other hand, in cross sectional analyses of the 
Massachusetts Male Aging Study (MMAS) 51 when age and similar covariates were controlled 
for, TT and FT were no longer significantly associated with cognitive function in men. The age 
                                                     
8 This cut-off is commonly used as a sensitive (but not specific) measure to exclude those with dementia 
48. Hogervorst E, Combrinck M, Lapuerta P, Rue J, Swales K, Budge M. The Hopkins Verbal 
Learning Test and screening for dementia. Dementia. 2002;13(1):13-20. 
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range of men (from 48 to 80 years) studied in the MMAS was wide and all hormones had been 
log transformed, which was not deemed necessary in our cohorts, possibly because our 
participants were a priori selected for relative health and not having dementia at baseline. It is 
possible that morbidity independently driving hypogonadism 38 and cognitive decline, such as 
diabetes, thyroid disease cardiovascular disease, is statistically together better explained by their 
common denominators: low testosterone and/or high SHBG levels. Sex steroid fluctuations 
perhaps thus act as ‘umbrella variables’, capturing the variance associated with multiple 
morbidity (diabetes, thyroid disease, liver dysfunction, wasting) each individually leading to 
cognitive decline 52. Other recent findings suggested that high levels of SHBG in themselves are 
independently of sex hormone levels associated with dementia risk and could be a marker for 
biological aging 53. SHBG also increases with estrogen treatment and is associated with high E2 
levels (Serin, 1992], which may suggest why it had an independent association with cognition in 
the present analyses which did not include estrogens. In the MMSA 51, estrone was seen to have 
a negative association with spatial function in adjusted analyses. Other longitudinal cohorts also 
reported that high estrogen- but not testosterone- levels were a risk factor for dementia or 
markers of dementia, such as cognitive decline and hippocampal atrophy, in both men and 
women 22, 54-56. Interestingly, in the brains of men with AD and those in early non clinical stages 
of dementia, testosterone- but not estradiol- levels were also already seen to be lower than in 
controls 57. Differences in assays used, including estrogens in the same analyses and possibly, 
differences in age range and dementia and health assessment at screening of participants make it 
difficult to compare studies and arrive at clear conclusions.   
However, one theoretical explanatory mechanism which combines the different findings 
could be the following 9. Aromatase is responsible for an increased conversion of testosterone 
into estradiol and there is some evidence that the genetic polymorphism associated with 
increased expression of aromatase is more frequent in men with AD than controls 58. Other 
genetic polymorphisms have been associated with an acceleration of the age-related decline in 
testosterone 59 and were found to occur more frequently in men with AD 60. In addition, having 
                                                                                                      Testosterone and cognition 18 
the APOE epsilon 4 allele, a well established genetic risk factor for AD, was seen to be 
associated with lower TT, also in control men of the OPTIMA case control cohort who had not 
(yet?) developed dementia symptoms 61. It may thus be the case that men at risk for AD have 
genetic polymorphisms that predispose them to accelerated age-related lowering of TT levels 
and an increased conversion of TT into estrogen levels. As described in the introduction, 
neurons undergoing pathological change do not benefit from an estrogenic environment. From 
this, however, it would follow that treatment with testosterone, which may result in increased 
conversion to estradiol in the brain in men who are genetically at risk, might not be 
recommended in older men, similar to recommendations for older women.  
Earlier it was hypothesized that thyroid dysregulation may be associated with an 
increase in SHBG, leading to a subsequent lowering of FAI 52, leading to increased levels of 
gonadotropins which are, as described, potentially neurotoxic. However, in the present cohort 
no association was found between SHBG and thyroid hormones levels. Hypothyroidism 
assessed at screening using high TSH levels was, similar to findings of the larger cohort 32, 
associated with lower cognitive function in men at baseline and with a sharp cognitive drop in 
women over time, but this was no longer significant when those with thyroid disease were 
excluded. High FT4 had an independent association with cognitive decline in men, which 
remained significant in those without overt thyroid disease, similar to that of other cohorts 32.  
Smoking, a known modifiable risk factor 62, also increased the risk for a sharp cognitive drop by 
more than a factor 2 in this cohort. However, unlike findings in other cohorts 62, vascular disease 
or diabetes had no significant associations with MMSE, which raises doubts about the validity 
of self-report of morbidity. For instance, those diagnosed with high BP or diabetes did not have 
significantly lower MMSE scores or a faster drop in this cohort as was found by others 62. Older 
people are perhaps often also not aware of harboring these ‘silent killers’. For instance, our 
earlier analyses 32 showed that half of participants with thyroid disease as assessed by blood 
values were unaware of having this.  
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There are thus several limitations to these analyses. There has been no adjustment in the 
analysis for the study selection, nor for differential dropout as the study was considered too 
small to enable this to be undertaken reliably. Furthermore, no extensive medical examination 
was carried out at baseline and only self-report data were available on diagnosed morbidity and 
medication use which may be particularly questionable in those suspected of having dementia 
63. Patients with dementia or other memory problems by the very nature of their symptoms may 
be less reliable in recall and carer confirmation when available is also not always accurate.There 
was also no formal dementia diagnosis. On the other hand, thyroid status was reviewed in detail 
in this cohort 32 and the AGECAT algorithm in earlier studies was shown to be a good predictor 
of depression and dementia in older people 30. Second, although FAI is considered to be a good 
predictor of free and bioavailable testosterone in women, this of course depends on the accuracy 
and sensitivity of the testosterone and SHBG assays primarily 37. Studies have shown that the 
DPG Immulite overestimated values in men (as compared to the gold standard ID/GC Mass 
Spec) and underestimated values in women. In general, the consensus now is that these types of 
automated assays should not be used in women or children 37. Indeed, more than half of the data 
of women were missing in the current cohort leading to low resolution in the data. When these 
missing data were ignored, negative associations were found for high levels of SHBG (beta=-
.23, p=0.01) and testosterone (beta=-.19, p<0.05) with both MMSE and memory function at 
baseline, although these did not predict cognitive decline over time. In controlled analyses, only 
the negative associations of SHBG levels with both delayed recall and MMSE performance 
remained significant in women. However, these data only reflect those of women with relatively 
high TT levels and did not take into account the half with undetectable data. This we tried to 
remedy by using quartiles. However, with potential issues because of long term storage and 
possible crystallization of fluids perhaps explaining high to very high TT levels in women, data 
need to be regarded with caution. For future assays, the gold standard GC Mass Spec will be 
used in our studies. 
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In sum, in men and women optimal TT levels were associated with better MMSE 
performance at baseline. Men who would show a sharp cognitive drop indicative of dementia 
had low TT levels and higher SHBG levels at baseline. This may be associated with an 
accelerated decline in TT levels impacting on brain function and/or a sign of increased 
conversion of TT into estrogens related to particular genetic polymorphisms in men at risk for 
dementia. More research needs to be done to further investigate this. In women, the reverse was 
the case, with some evidence for higher FAI in those who would show a sharp drop in cognitive 
function. Combined data at this point do not suggest that testosterone in older men and women 
would be a viable treatment to prevent cognitive decline. 
 
List of abbreviations 
 
AD=Alzheimer’s disease 
AGECAT= Automated Geriatric Examination and Computer Assisted Taxonomy 
AR=androgen receptor 
BLSA=Baltimore Longitudinal Study of Aging 
BP=blood pressure 
BMI=body mass index 
CV=coefficient of variation 
ER=estrogen receptor 
E2=estradiol 
FAI=free androgen index 
FT=free testosterone 
FT4= free thyroxine 
ID/GC Mass Spec= isotope dilution-gas chromatography mass spectrometry 
LH=luteinizing hormone 
MMAS= Massachusetts Male Aging Study 
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MMSE=Mini Mental Status Examination 
MRC CFAS= Medical Research Council Cognitive Function and Ageing Study  
OPTIMA= Oxford Project To Investigate Memory and Ageing 
OR=odd ratio 
TSH=thyroid stimulating hormone 
TT=Total testosterone 
SHBG= sex hormone binding globulin 
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